- Home
- SNGX vs CNSP Comparison
SNGX vs CNSP Comparison
Compare SNGX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- CNSP
- Stock Information
- Founded
- SNGX 1987
- CNSP 2017
- Country
- SNGX United States
- CNSP United States
- Employees
- SNGX N/A
- CNSP N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- CNSP Health Care
- Exchange
- SNGX Nasdaq
- CNSP Nasdaq
- Market Cap
- SNGX 7.5M
- CNSP 5.4M
- IPO Year
- SNGX 1987
- CNSP 2019
- Fundamental
- Price
- SNGX $3.74
- CNSP $0.14
- Analyst Decision
- SNGX
- CNSP
- Analyst Count
- SNGX 0
- CNSP 0
- Target Price
- SNGX N/A
- CNSP N/A
- AVG Volume (30 Days)
- SNGX 116.0K
- CNSP 3.4M
- Earning Date
- SNGX 08-09-2024
- CNSP 08-14-2024
- Dividend Yield
- SNGX N/A
- CNSP N/A
- EPS Growth
- SNGX N/A
- CNSP N/A
- EPS
- SNGX N/A
- CNSP N/A
- Revenue
- SNGX $494,623.00
- CNSP N/A
- Revenue This Year
- SNGX N/A
- CNSP N/A
- Revenue Next Year
- SNGX $76.64
- CNSP N/A
- P/E Ratio
- SNGX N/A
- CNSP N/A
- Revenue Growth
- SNGX N/A
- CNSP N/A
- 52 Week Low
- SNGX $1.83
- CNSP $0.10
- 52 Week High
- SNGX $32.00
- CNSP $137.50
- Technical
- Relative Strength Index (RSI)
- SNGX 46.76
- CNSP 23.50
- Support Level
- SNGX $3.27
- CNSP $0.15
- Resistance Level
- SNGX $4.67
- CNSP $0.17
- Average True Range (ATR)
- SNGX 0.56
- CNSP 0.02
- MACD
- SNGX 0.04
- CNSP 0.07
- Stochastic Oscillator
- SNGX 22.07
- CNSP 18.08
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.